The phrase "analysis will be available" is correct and usable in written English.
You can use it when indicating that a certain analysis or evaluation will be provided at a later time.
Example: "The final report will be submitted next week, and the analysis will be available shortly thereafter."
Alternatives: "analysis will be provided" or "analysis will be accessible".
The results of analysis will be available online, and your sample(s) can be picked up in 22 Lewis Hall.
In the near future, when novel Web-based platforms for rapid data processing and analysis will be available, whole genome sequencing technologies will likely become a highly powerful tool for outbreak investigations and surveillance studies in routine clinical practices.
The aim of the platform, whose research and analysis will be available to the public, is to advance real estate investment-related analytics in such areas as price and rent indexing (how prices change over time) and automated valuation models.
(The details of our analysis will be available in our forthcoming article in the American Journal of Political Science). In the first experiment, a field study carried out in an online labor market, we assessed whether individuals are more likely to demand higher wages when they learn that their boss's political party is different from their own.
The results of Neuro-Insight's analysis will be available next week, but in the meantime, Yadav is bullish on his company's platform.
This week, CSU officials said that, going forward, the analysis will be available to those who request a copy.
Automatic analysis execution will be available in the next version of SIGLa.
All the sequence data and analysis results will be available to open access upon the publication of this manuscript at: 4. Presentation of the results.
The final report of the analysis, which will be available to the user, is a Microsoft Excel file including a table with all the relevant information useful to filter the selected variants and to prioritise them in order to choose the best possible candidates for subsequent validation.
An international randomised phase III trial of sunitinib (administered in repeated cycles of 50 mg daily for 4 weeks then 2 weeks off) vs IFN- α (administered three times weekly) has recently completed accrual; interim analysis results will be available soon.
The results of the final analysis of outcomes will be available in 2015; however, we now report the results of a planned interim analysis of safety data from 1312 patients and describe the development of a nomogram for predicting the risk of irinotecan-induced severe neutropenia, with external validation using an independent cohort of 350 patients.
